US Federal Register Drops Alibaba Qwen AI Search Tool 
Gold Prices Slip as Strong Dollar and Hawkish Fed Pressure Bullion 
CNN, MS NOW and Politico Sue Trump Over White House Media Ban 
U.S. Dollar Hits Eight-Week High After Fed Rate Hike 
Europe Jet Fuel Deficit Drives South Korean Imports to Four-Year High 
Allegro Raises 2026 Outlook as International GMV Surges 
Trump Bans CNN, MS NOW and Politico From White House 
Paramount Skydance Faces $30 Million Film Penalty in Warner Bros. Deal 
SoftBank Launches $11 Billion Bond Sale to Fund OpenAI Investment 
Vietnam Stocks Join FTSE Emerging Market Indexes, Unlocking Billions in Foreign Investment 
fnny Beta Launches With a Simple Idea: Find an Event, Show Up, Get Rewarded 
White House Bars CNN, MS NOW and Politico Reporters 
Oil Prices Rise as U.S.-Iran Talks Fuel Diplomacy Hopes 
Volvo Cars Plans 13 New Models by 2030 to Boost Sales 
US, Japan and South Korea Back Taiwan Ahead of Trump-Xi Summit 
Asia Stocks Rise on AI Demand as Oil Eases 
U.S. Stock Futures Rise Ahead of Trump-Xi Summit, Middle East Risks Weigh 
Add as a preferred source on Google
Samsung Biologics is now confirmed to produce Moderna’s COVID-19 vaccines in South Korea. The biotechnology company headquartered in Incheon is said to be working to hasten preparations and begin the production of the shots in the second half of this year.
Confirmation of the vaccine production deal
The Korea Herald reported that Samsung Biologics is preparing its drug manufacturing facility in Songdo, Incheon. This is said to be one of the largest in the world and it is here where the biotech firm will be handling the filling and finishing process of Moderna vaccine production. To be more specific, the mRNA-1273 which is the American pharmaceutical company’s messenger-RNA-based COVID-19 shot.
The Samsung and Moderna agreement was officially signed and this was witnessed by South Korean President Moon Jae In looking. The deal is actually part of the Korean-US vaccine partnership that was one of the agendas at the recent summit that was held in the U.S. last week.
The agreement between Samsung Biologics and Moderna
Samsung Biologics will be filling up vials and packaging them for sale and distribution. The main vaccine content will be coming directly from Moderna and Lonza, its Swiss production partner, and the overall finishing process will be done in Korea.
"This vaccine is paramount to people around the world in the fight against the COVID-19 pandemic, and we truly appreciate our client Moderna for entrusting and choosing to partner with Samsung Biologics for the fill and finish of this important vaccine," Samsung Biologics CEO, John Rim, said in a press release."Due to the high level of urgency in supplying the vaccine to the global population, we have set immediate action plans and schedule to make mRNA-1273 available for commercial distribution in the early second half of 2021."
On the other hand, Moderna’s chief technical operations and quality officer, Juan Andres, said that they are pleased to team up with Samsung Biologics for the fill and finish production. He explained that this arrangement will help them continue to boost their manufacturing capacity outside of the U.S. as they remained committed to beating COVID-19.
Meanwhile, South Korean government officials gladly welcomed the partnership as this is a big opportunity for the country to scale up and be a global factory of vaccines for COVID-19.
